<DOC>
	<DOCNO>NCT01112020</DOCNO>
	<brief_summary>The purpose study determine content chlorhexidine-containing dressing use .</brief_summary>
	<brief_title>Components Chlorhexidine Gluconate Dressing</brief_title>
	<detailed_description>To characterize chemical composition CHG ( 2 % CHG ) Catheter Dressing Patch compare Biopatch Protective Disk CHG , Tegaderm IV ( intravenous ) Securement Dressing wear period 7 day .</detailed_description>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<criteria>Able read , review sign Informed Consent Willing shower use soap/cleansers Screening Visit end study Use studyapproved contraceptive method Participation investigational study within 28 day prior dose . Clinically significant illness within 28 day prior dose . History allergic response chlorhexidine , chlorhexidinecontaining product , glycerol , adhesive , latex History clinically significant skin disorder History Type I diabetes mellitus , insulindependent diabetes mellitus ( IDDM ) History significant dermatologic cancer ( melanoma , squamous ) Known history immunologic disorder Use immunosuppressive proscribed medication Use skin product application site Significant history allergy soap , lotion , emollient , ointment , creams History drug alcohol addiction within past year Pregnant , lactating , breastfeeding , intend become pregnant course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Chlorhexidine digluconate ( CHG )</keyword>
	<keyword>Biopatch Protective Disk</keyword>
	<keyword>Tegaderm CHG IV ( intravenous ) Securement Dressing</keyword>
	<keyword>parachloroaniline ( PCA )</keyword>
	<keyword>No condition study .</keyword>
	<keyword>Assessing component CHG-containing dressing use .</keyword>
</DOC>